Dachaigh › Lymphoma Burkitt › Massachusetts
Sgrùdaidhean clionaigeach Lymphoma Burkitt ann an Massachusetts
Tha 10 sgrùdaidhean airson Lymphoma Burkitt a’ lorg phàirtichean aig làraichean ann an Massachusetts.
Bailtean ann an Massachusetts
Teacsa sgrùdaidh oifigeil (Beurla)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
A’ fastadhÌre 2
366 Days – 46 Years · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Dana-Farber Cancer Institute, Boston
A’ fastadhÌre 3
Aoisean 18 gu 39 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
A’ fastadhÌre 2
365 Days · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06317662Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
A’ fastadhÌre 1/2
6 Months – 25 Years · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT06395103Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Tufts Medical Center, Boston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT03666000Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- agus 1 a bharrachd
A’ fastadhÌre 3
365 Days – 25 Years · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT03959085Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Gearr 2026 · NCT05544019ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Samh 2025 · NCT03595917Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Dana Farber Cancer Institute, Boston
A’ fastadhÌre 1/2
Aoisean 15 gu 50 · Gach gnè · Air ùrachadh 9 Sult 2025 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Floating Hospital for Children at Tufts Medical Center, Boston
- Dana Faber Cancer Institute/ Boston Children's Hospital, Boston
A’ fastadhÌre 2
Aoisean 1 gu 25 · Gach gnè · Air ùrachadh 4 Cèit 2025 · NCT03509961Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.